Durysta (implant)
| Durysta (implant) | |
|---|---|
| DOSAGE | Implanted via intracameral injection |
| GENERIC | Bimatoprost 10 mcg implant |
| SIZE | 10 mcg implant |
| INDICATIONS | Reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. |
| MECHANISM OF ACTION | alpha-2 agonist | Bimatoprost is believed to lower IOP in humans by increasing outflow of aqueous humor through both the trabecular meshwork (conventional) and uveoscleral routes (unconventional). |
| MICROBIOLOGY | Unknown at this time |
| CONTRAINDICATIONS & WARNINGS | Durysta is contraindicated in patients with ocular or periocular infections, corneal endothelial cell dystrophy, prior corneal transplantation, absent or ruptured posterior lens capsule, and hypersensitivity to components of the product. |
| PEDIATRIC USE | Safety and effectiveness of DURYSTA in pediatric patients have not been established. |
| PREGNANCY | Pregnancy category C |There are no adequate and well-controlled studies of DURYSTA (bimatoprost intracameral implant) administration in pregnant women to inform a drug associated risk. |
| NOTE | |